TwinEdge Bioscience provides a cloud‑based platform that creates high‑fidelity digital twins of individual patient tumors by integrating genomics, transcriptomics, proteomics and histopathology data. Its AI‑augmented simulation engine predicts drug response, resistance mechanisms and biomarker associations across a library of over 10,000 validated tumor avatars, enabling pharmaceutical and CRO teams to prioritize candidates, design trials and stratify patients before human enrollment.
Funding
Funding not disclosed
Founders
Product
Problem
Oncology drug programs often progress to clinical trials with limited insight into how diverse patient tumor profiles will respond, leading to high attrition rates and costly trial redesigns. Existing preclinical models cannot fully capture the molecular heterogeneity of human cancers, restricting the ability to prioritize the most promising translational candidates early in development.
Solution
TwinEdge Bioscience builds computationally actionable digital twins—“avatars”—that replicate the molecular and phenotypic characteristics of individual patient tumors. By integrating multi‑omic data from tumor samples with mechanistic pathway models and AI‑driven response simulations, the platform enables “in‑avatar” drug testing across a population‑scale library of avatars. Researchers can evaluate efficacy, resistance mechanisms, and biomarker associations virtually, generating quantitative predictions that inform target selection, trial design, and patient stratification before enrolling human subjects. The service is delivered through a cloud‑based analytics suite that connects to existing preclinical pipelines and supports seamless data exchange with partner CROs and knowledge bases.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing oncology therapeutics, as well as translational CROs, academic research groups, and patient advocacy foundations seeking data‑driven insights for trial design and biomarker discovery.
Features
- Proprietary pipeline that fuses genomics, transcriptomics, proteomics, and histopathology from patient tumor samples into high‑fidelity digital twin models
- AI‑augmented simulation engine that predicts drug‑target interactions, dose‑response curves, and resistance pathways for each avatar
- Scalable cloud platform hosting >10,000 validated tumor avatars, enabling virtual cohort studies and statistical power comparable to early‑phase trials
- Integration layer with external preclinical assets (PDX, CDX, organoids, cell lines) to align in‑silico predictions with experimental data
- RESTful API and SDKs for automated workflow incorporation into pharmaceutical R&D pipelines and CRO analytics environments
- Secure, HIPAA‑compliant data storage with role‑based access controls and audit trails for patient‑derived information
- Continuous validation network leveraging leading translational CROs to benchmark avatar predictions against in‑vivo outcomes